327 related articles for article (PubMed ID: 21298439)
1. Malignant mixed Mullerian tumor of the ovary with two cases and review of the literature.
Duman BB; Kara IO; Günaldi M; Ercolak V
Arch Gynecol Obstet; 2011 Jun; 283(6):1363-8. PubMed ID: 21298439
[TBL] [Abstract][Full Text] [Related]
2. Ovarian malignant Mullerian mixed tumor (heterologous) whose epithelial component is composed predominantly of signet ring cell carcinoma.
Terada T
Arch Gynecol Obstet; 2011 Jun; 283(6):1403-6. PubMed ID: 20652287
[TBL] [Abstract][Full Text] [Related]
3. Chemotherapy for malignant mixed Müllerian tumors of the ovary.
Sit AS; Price FV; Kelley JL; Comerci JT; Kunschner AJ; Kanbour-Shakir A; Edwards RP
Gynecol Oncol; 2000 Nov; 79(2):196-200. PubMed ID: 11063643
[TBL] [Abstract][Full Text] [Related]
4. Prolonged survival of stage IV malignant mixed Müllerian tumor of the ovary after carboplatin, mesna, ifosfamide, and cis-platin chemotherapy: case report.
Di Vagno G; Cormio G; Loverro G; Melilli GA; Di Gesù G; Selvaggi L
J Chemother; 1998 Oct; 10(5):418-21. PubMed ID: 9822362
[TBL] [Abstract][Full Text] [Related]
5. Malignant mixed müllerian tumors of the ovary.
Wei CF; Hwang SH; Ho CM; Shih BY; Chien TY
Zhonghua Yi Xue Za Zhi (Taipei); 2000 Apr; 63(4):344-8. PubMed ID: 10820916
[TBL] [Abstract][Full Text] [Related]
6. Paclitaxel and platinum chemotherapy for malignant mixed müllerian tumors of the ovary.
Duska LR; Garrett A; Eltabbakh GH; Oliva E; Penson R; Fuller AF
Gynecol Oncol; 2002 Jun; 85(3):459-63. PubMed ID: 12051874
[TBL] [Abstract][Full Text] [Related]
7. Presence of a sarcomatous component outside the ovary is an adverse prognostic factor for primary ovarian malignant mixed mesodermal/mullerian tumors: a clinicopathologic study of 47 cases.
Kunkel J; Peng Y; Tao Y; Krigman H; Cao D
Am J Surg Pathol; 2012 Jun; 36(6):831-7. PubMed ID: 22588065
[TBL] [Abstract][Full Text] [Related]
8. Medical therapy of advanced malignant epithelial tumours of the ovary.
Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
[TBL] [Abstract][Full Text] [Related]
9. Malignant mixed müllerian tumor with malignant neuroectodermal components (teratoid carcinosarcoma) of the ovary: Report of a case with clinicopathologic findings.
Matsuura Y; Kitajima M; Hachisuga T; Tanimoto A; Okura N; Kihara I
J Obstet Gynaecol Res; 2010 Aug; 36(4):907-11. PubMed ID: 20666968
[TBL] [Abstract][Full Text] [Related]
10. Ovarian malignant mixed mullerian tumor with primitive neuroectodermal differentiation: case report with review of the literature.
Nasser H; Morris RT; Fathallah L
Pathol Res Pract; 2011 Mar; 207(3):202-6. PubMed ID: 20950943
[TBL] [Abstract][Full Text] [Related]
11. Malignant mixed müllerian tumors of the ovary: experience with surgical cytoreduction and combination chemotherapy.
Muntz HG; Jones MA; Goff BA; Fuller AF; Nikrui N; Rice LW; Tarraza HM
Cancer; 1995 Oct; 76(7):1209-13. PubMed ID: 8630899
[TBL] [Abstract][Full Text] [Related]
12. A case of a patient diagnosed with malignant mixed Müllerian tumor of the ovary who conceived after conservative surgery and adjuvant chemotherapy.
Shibahara H; Wakimoto E; Mitsuo M; Ogasawara T; Takemura T; Koyama K
Gynecol Oncol; 1997 May; 65(2):363-5. PubMed ID: 9159353
[TBL] [Abstract][Full Text] [Related]
13. Carcinosarcoma of the ovary treated with platinum and taxane: the memorial Sloan-Kettering Cancer Center experience.
Leiser AL; Chi DS; Ishill NM; Tew WP
Gynecol Oncol; 2007 Jun; 105(3):657-61. PubMed ID: 17395252
[TBL] [Abstract][Full Text] [Related]
14. Alpha-fetoprotein production by a malignant mixed Müllerian tumor of the ovary.
Rebischung C; Pautier P; Morice P; Lhomme C; Duvillard P
Gynecol Oncol; 2000 Apr; 77(1):203-5. PubMed ID: 10739713
[TBL] [Abstract][Full Text] [Related]
15. Excellent progression-free survival with liposomal doxorubicin for a patient with recurrent ovarian malignant mixed müllerian tumor: case report and literature review.
Hsieh CL; Chang TC; Lai CH; Jung SM; Chou HH
Gynecol Oncol; 2004 Sep; 94(3):854-7. PubMed ID: 15350389
[TBL] [Abstract][Full Text] [Related]
16. Determining predominating histologic component in malignant mixed müllerian tumors: is it worth it?
Ozguroglu M; Bilici A; Ilvan S; Turna H; Atalay B; Mandel N; Sahinler I
Int J Gynecol Cancer; 2008; 18(4):809-12. PubMed ID: 17892455
[TBL] [Abstract][Full Text] [Related]
17. Phase II prospective study of paclitaxel and carboplatin in older patients with newly diagnosed Müllerian tumors.
Matulonis UA; Krag KJ; Krasner CN; Atkinson T; Horowitz NS; Lee H; Penson RT
Gynecol Oncol; 2009 Feb; 112(2):394-9. PubMed ID: 19058838
[TBL] [Abstract][Full Text] [Related]
18. Good response of malignant mixed mullerian tumor of the ovary to paclitaxel and cisplatin chemotherapy.
Eltabbakh GH; Yadav R
Eur J Gynaecol Oncol; 1999; 20(5-6):355-6. PubMed ID: 10609493
[TBL] [Abstract][Full Text] [Related]
19. Carboplatin plus paclitaxel for advanced or recurrent uterine malignant mixed mullerian tumors. The British Columbia Cancer Agency experience.
Hoskins PJ; Le N; Ellard S; Lee U; Martin LA; Swenerton KD; Tinker AV;
Gynecol Oncol; 2008 Jan; 108(1):58-62. PubMed ID: 17935761
[TBL] [Abstract][Full Text] [Related]
20. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma.
Vasey PA; Jayson GC; Gordon A; Gabra H; Coleman R; Atkinson R; Parkin D; Paul J; Hay A; Kaye SB;
J Natl Cancer Inst; 2004 Nov; 96(22):1682-91. PubMed ID: 15547181
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
